Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $5.7 million.

  • Exagen's Accumulated Expenses fell 798.12% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 798.12%. This contributed to the annual value of $6.9 million for FY2024, which is 816.62% down from last year.
  • According to the latest figures from Q3 2025, Exagen's Accumulated Expenses is $5.7 million, which was down 798.12% from $4.9 million recorded in Q2 2025.
  • Exagen's Accumulated Expenses' 5-year high stood at $7.5 million during Q4 2023, with a 5-year trough of $4.9 million in Q2 2025.
  • Its 5-year average for Accumulated Expenses is $6.1 million, with a median of $6.0 million in 2024.
  • As far as peak fluctuations go, Exagen's Accumulated Expenses crashed by 2166.72% in 2022, and later skyrocketed by 4084.53% in 2023.
  • Quarter analysis of 5 years shows Exagen's Accumulated Expenses stood at $6.8 million in 2021, then dropped by 21.67% to $5.3 million in 2022, then surged by 40.85% to $7.5 million in 2023, then decreased by 8.17% to $6.9 million in 2024, then fell by 17.81% to $5.7 million in 2025.
  • Its Accumulated Expenses was $5.7 million in Q3 2025, compared to $4.9 million in Q2 2025 and $4.9 million in Q1 2025.